Related Experiment Video
Updated: Aug 14, 2026

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
Published on: February 9, 2021
Uncaging Iridium(III) Complexes for Combined Photodynamic and Photoactivated Chemotherapy
Victoria V L Müller1,2, Dominik Moreth2,3, Irene Regeni4,5
1Department of Chemistry, Princeton University, Princeton, USA.
New iridium complexes act as light-activated anticancer prodrugs. They release active compounds upon illumination, showing potent photocytotoxicity with reduced dark toxicity, paving the way for combined photochemotherapy and photodynamic therapy.
Area of Science:
- Inorganic Chemistry
- Photochemistry
- Medicinal Chemistry
Background:
- Photochemotherapy offers targeted cancer treatment with reduced systemic toxicity.
- Iridium(III) complexes are explored for their photophysical properties and potential as anticancer agents.
- Developing light-activatable prodrugs requires precise control over drug release and activation mechanisms.
Purpose of the Study:
- To develop novel iridium(III) complexes as light-activatable anticancer prodrugs.
- To investigate the role of sulfur- and selenium-based "caging" groups in modulating photoreactivity.
- To evaluate the photocytotoxicity and underlying mechanisms of these complexes.
Main Methods:
- Synthesis and characterization of two iridium(III) complexes: [Ir(cys)(ppy)(terpy)]PF6 and [Ir(sec)(ppy)(terpy)]PF6.
- Photochemical studies to elucidate distinct bond cleavage pathways upon visible light activation.
- Assessment of singlet oxygen production quantum yields and photodynamic therapy (PDT) mechanism.
- Evaluation of dark toxicity and photocytotoxicity in A549 cancer cells at different wavelengths.
Main Results:
- Both complexes are stable in the dark but release active species upon light exposure.
- Distinct photochemical pathways were observed: sulfur complex involves sulfinato intermediate, while selenium complex forms an unprecedented selenite intermediate.
- High singlet oxygen production quantum yields (40%-48%) indicate efficient PDT potential.
- Minimal dark toxicity (EC50 > 150 µM) but potent photocytotoxicity was observed under blue and green light.
Conclusions:
- Chalcogen coordination significantly influences the photoreactivity and therapeutic efficacy of iridium(III) complexes.
- These photocaged iridium(III) pro-sensitizers show promise for combined photochemotherapy and photodynamic therapy (PDT) applications.
- The developed complexes offer a new strategy for targeted cancer treatment with enhanced spatial and temporal control.
More Related Videos
11:20An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation
Published on: August 30, 2017
13:17In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
Related Concept Videos
Photochemical Electrocyclic Reactions: Stereochemistry
Selection Rules: Photochemical Activation
Cycloaddition Reactions: MO Requirements for Photochemical Activation